Tirzepatide is a dual incretin receptor agonist that activates both GLP-1 and GIP pathways to support advanced appetite control, improved metabolic function, and enhanced insulin sensitivity. It’s widely researched for its strong weight-management potential and impact on metabolic efficiency.
What It Supports
How It Works
Tirzepatide’s dual-agonist mechanism amplifies the body’s natural incretin response:
Together, these signals promote fewer calories consumed — and more body fat used as fuel.
Ideal Research Applications
For Research Use Only
Not approved by the FDA for medical use. Not intended to diagnose, treat, cure, or prevent any disease. Laboratory research only.

